BioCryst Reports First Quarter 2008 Financial Results and Clini... (homa (CTCL) trial update andchronic lymp...)

BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

Date:5/8/2008

homa (CTCL) trial update and chronic lymphocytic leukemia (CLL) trial initiation

The forodesine HCl CTCL pivotal trial is enrolling as planned. This trial has been reviewed under a Special Protocol Assessment (SPA) from the United States Food & Drug Administration (FDA) to support regulatory approval.

BioCryst has also initiated a second clinical trial for patients with CLL based upon data presented at the December 2007 ASH meeting, which demonstrated the potential of forodesine HCl as a treatment for CLL, both as a single agent and in combination with bendamustine. This second CLL trial is a single-arm study evaluating single agent forodesine HCl as a treatment for patients with CLL; response rate is the primary endpoint. The first patient was dosed during the first quarter 2008, and BioCryst will provide a trial update by year end.

Intramuscular (i.m.) peramivir clinical development update

BioCryst initiated a Phase III i.m. peramivir trial early this year and voluntarily discontinued it after 82 of the planned 600 patients had enrolled because of a decision to pursue higher doses in a Phase II setting. Patients with influenza A and B were treated with either placebo or 300mg of i.m. peramivir. Although only 14% of the planned patients were enrolled in the study, results supported the activity of 300mg peramivir. The study was designed to show a difference within the influenza A subgroup, where preliminary clinical data showed a 30 hour reduction in time to alleviation of symptoms in patients that received peramivir compared to those who received placebo. Preliminary results from the overall population showed a reduction in time to alleviation of symptoms of approximately 14 hours. Because the trial was not carried out to completion, the sample size was small; the observed treatment effect was not statistically significant.

These results are consistent with data from previous clinical trials:

-- Reductions in time to
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results

Post Your Comments:

BioCryst Reports First Quarter 2008 Financial Results and Clini...(homa (CTCL) trial update andchronic lymp...)